Battelle Memorial Institute
Battelle Memorial Institute, doing business as Battelle, is the world's largest independent nonprofit research and development organization. With over 20,000 employees globally, Battelle provides innovative solutions in national security, health, energy, and education sectors. As a nonprofit organization and manufacturer of goods, Battelle frequently provides research, engineering, testing, manufacturing, and information technology services to U.S. federal government agencies through prime and subcontract awards. The organization leverages its extensive scientific resources and technical capabilities across multiple research fields to address complex challenges for government and commercial clients.
Through prime federal contract awards, Battelle has provided the government with a wide range of goods and services across domains like defense, homeland security, health, energy, and transportation. Notable examples include delivering armored vehicles and integrated military systems to the United States Special Operations Command, developing chemical screening and nonclinical study services for the National Institutes of Health, manufacturing aircraft components like the Modular Aerial Spray System for the Department of the Air Force, supporting environmental programs like dredged material testing for the Army Corps of Engineers, and delivering research services for the Defense Advanced Research Projects Agency. Many contracts involve hardware development, laboratory testing, and technical research across chemical, biological, and engineering fields. Battelle serves as both a prime and subcontractor, frequently partnering with specialized manufacturers and technical consultants. Awards span contract types like definitive contracts, purchase orders, and delivery orders issued against IDIQ vehicles like OASIS and GSA Schedules. Few set-asides are specified on these awards issued by the Departments of Defense, Energy, Homeland Security, Health and Human Services, and other major federal agencies and offices.
On the grant side, Battelle has been awarded cooperative agreements by the Department of Energy to support carbon capture and storage technology initiatives, as well as Environmental Protection Agency project grants focused on environmental monitoring and remediation of critical minerals at mining sites. The National Science Foundation has issued cooperative agreements enabling Battelle to operate the National Ecological Observatory Network continental research platform and lead global collaborative networks advancing ecological drought research. These awards provide funding through federal programs like the DOE's Fossil Energy Research and Development, EPA's Consolidated Research/Training/Fellowships, and NSF's Biological Sciences for Battelle to conduct research, field studies, operational maintenance, training, and international partnership activities. Battelle frequently collaborates with universities and other research institutions on these federally-funded studies, combining complementary capabilities to advance scientific knowledge and develop new technologies with potential societal impact.
Battelle holds several major indefinite-delivery indefinite-quantity (IDIQ) contracts providing a broad scope of research, development, testing, and technical support services. These include a $100 million contract for biological animal model and medical countermeasure development through the HHS Biomedical Advanced Research and Development Authority, a $149 million vehicle for manufacturing and nonclinical studies of neurological therapeutic biotechnology products under NIH, and a $100 million EPA contract for chemical screening, review, and evaluation. The Department of Homeland Security awarded Battelle a $95 million single-award IDIQ for research and developmental testing related to transportation security, while the Defense Advanced Research Projects Agency issued an OT IDV valued at $32 million for initiatives like the Foundational Security for Food Systems program. Through these IDIQs, federal agencies gain flexible access to Battelle's extensive scientific resources and technical capabilities across a multitude of research fields.
F125YU6SWK59 541715
Not listed 505 King Ave, Columbus, OH 43201, USA
12/6/01 11/12/25 Research Triangle Institute
Research Triangle Institute, doing business as RTI International, is an independent, non-profit research organization that provides a wide range of technical and advisory services to the federal government. Established in 1958 and headquartered in Research Triangle Park, North Carolina, RTI International leverages expertise across disciplines such as health, education, social and economic policy, advanced technology, energy, and the environment. The organization has received numerous federal contract and grant awards to support research, program evaluation, technical assistance, and implementation of evidence-based practices across multiple agencies. Through its multidisciplinary approach, RTI International aims to address complex challenges and improve the human condition by turning knowledge into practice.
Through federal contracts, RTI International has provided diverse services including technical guidance, assessments, data analysis, and program evaluation. For the Environmental Protection Agency, RTI has conducted risk assessments, environmental modeling, and policy analysis related to air quality, water resources, and chemical safety. The organization has supported the Department of Health and Human Services with public health research, healthcare delivery studies, and substance abuse prevention initiatives. RTI has also assisted the Department of Justice with criminal justice research, forensic science advancement, and victim services program evaluations. Additionally, RTI has worked with the U.S. Agency for International Development on global health, education, and governance projects in developing countries. These contract awards have typically been competitively awarded without set-asides, leveraging RTI's status as an experienced federal contractor.
RTI International's federal grant portfolio reflects its multidisciplinary research capabilities. The National Institutes of Health has awarded RTI numerous grants for biomedical research, clinical trials support, and public health studies in areas such as substance abuse, mental health, and infectious diseases. The National Science Foundation has funded RTI for science, technology, engineering, and mathematics (STEM) education research and workforce development initiatives. The Department of Education has supported RTI's work on education policy analysis, literacy interventions, and special education research. Additionally, RTI has received grants from the Centers for Disease Control and Prevention for chronic disease prevention, injury control, and environmental health studies. Many of these grants involve collaborations with academic institutions, healthcare organizations, and community partners to leverage diverse expertise and resources.
RTI International holds several significant federal contract Indefinite Delivery Vehicles (IDVs) that enable streamlined procurement of its services. The organization has a Blanket Purchase Agreement with the Environmental Protection Agency for risk assessment and technical analysis support, allowing task orders to be issued for environmental science and policy work. RTI also holds a single-award IDV with the U.S. Agency for International Development for Central America Regional Support Services, enabling the agency to procure a range of development assistance services. The National Institutes of Health has awarded RTI a BPA for product development support and coordination for its NHLBI Catalyze program. Additionally, RTI has IDVs with the Centers for Disease Control and Prevention for data-related services and with the Department of Labor for evaluation services supporting its Chief Evaluation Office. These vehicles demonstrate the breadth of RTI's capabilities and its status as a trusted partner across multiple federal agencies.
JJHCMK4NT5N3 541620
Not listed 3040 E Cornwallis Rd, Durham, NC 27709, USA
11/5/01 2/21/26 PPD Development LP
PPD Development LP is a global contract research organization (CRO) that provides comprehensive clinical trial and research support services to federal government agencies. As a subsidiary of Thermo Fisher Scientific, PPD offers expertise in areas such as regulatory affairs, clinical site monitoring, data management, and analytical testing to support the development of vaccines, therapeutics, diagnostics, and medical countermeasures. The company has been registered to receive federal awards since 2003 and has established itself as a key partner in advancing public health initiatives and medical research programs across multiple agencies and therapeutic areas.
Through prime federal contract awards, PPD Development LP has provided a wide range of services to agencies such as the National Institutes of Health (NIH), Department of Defense (DoD), and Department of Health and Human Services (HHS). These services include clinical site monitoring for the National Institute of Allergy and Infectious Diseases (NIAID), regulatory management support for NIAID's Regulatory Management Center, and comprehensive clinical trial management for COVID-19 studies. PPD has also conducted exploratory analyses for the National Human Genome Research Institute, developed U.S. Army blood products concepts of operations, and provided expanded access treatment protocols for HHS during the COVID-19 pandemic. The company has received multiple high-value contracts, including a $222 million contract from HHS for a Phase 2 clinical trial on acute respiratory distress syndrome and a $186 million contract from NIAID for clinical site monitoring services. Additionally, PPD has provided subcontract services to prime contractors such as General Dynamics Information Technology for various DoD and civilian agency projects.
PPD Development LP's involvement in federal grant awards primarily consists of subcontract work supporting prime grantees. The company has provided services for projects such as the DMPA XT study and Sayana Press initiatives through Family Health International, as well as clinical trial support for HIV-to-HIV deceased donor kidney transplantation research at Johns Hopkins University. PPD has also assisted the University of Pittsburgh with site responsibilities for pediatric clinical studies, including participant recruitment, data collection, and adverse event reporting. These grant-funded projects demonstrate PPD's capabilities in managing complex clinical trials, handling specialized laboratory services, and supporting research in various therapeutic areas.
The company holds several significant Indefinite Delivery Vehicles (IDVs) with federal agencies. Notable among these is a $545 million contract with NIAID for comprehensive and rapid response capabilities in research programs, supporting a range of clinical and non-clinical services. PPD also holds a $346 million multiple-award contract for NIAID's Early Phase Clinical Trial Units program, facilitating Phase 0 through Phase II trials for infectious diseases. Other IDVs include a $49.9 million contract with the National Institute on Drug Abuse for Blueprint MedTech clinical studies, a $24 million contract for regulatory affairs support in the same program, and a $548 million multiple-award contract with the National Cancer Institute for cancer trials support. These IDVs position PPD Development LP to provide a wide array of services across multiple agencies, including clinical trial management, regulatory affairs support, and specialized research and development activities.
ZANENSW6C665 541714
Not listed PPD Building, 929 N Front St, Wilmington, NC 28401, USA
5/6/03 1/6/26 IIT Research Institute
IIT Research Institute (IITRI) is a non-profit contract research organization and division of the Illinois Institute of Technology that specializes in preclinical drug development services for federal agencies. IITRI primarily supports the Department of Health and Human Services by conducting pharmacology, toxicology, safety, and efficacy evaluations of small molecule, biologic, and RNA therapeutic candidates across various disease areas to support Investigational New Drug (IND) applications. The organization leverages its expertise in non-GLP and GLP studies, analytical assay development, and process validation to advance promising therapies from discovery through clinical trials. IITRI has extensive experience providing these services to federal agencies through both prime contracts and subcontracts.
IITRI has been awarded numerous contracts from agencies such as the National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID), National Institute of Neurological Disorders and Stroke (NINDS), and National Center for Advancing Translational Sciences (NCATS). These contracts have supported a wide range of preclinical research activities, including toxicology studies for cancer therapies, safety assessments of potential treatments for neurological disorders, and evaluation of vaccine candidates for infectious diseases. Notable projects include preclinical development of an RNA vaccine for prostate cancer prevention, non-clinical safety studies of compounds for conditions like neuropathic pain and acute cannabinoid overdose, and toxicology testing of COVID-19 related therapies. IITRI has also conducted subcontract work for other research institutions, performing specialized studies such as repeat dose toxicity evaluations of multivalent vaccines. The contracts awarded to IITRI are typically not associated with set-aside designations.
IITRI holds several significant indefinite delivery/indefinite quantity (IDIQ) contract vehicles with federal agencies. These include a $146.3 million single-award contract with NIAID for preclinical models of infectious diseases, a $48.6 million multiple-award contract with NCATS for safety evaluation and toxicology studies, and a $150 million multiple-award contract with NCI for the PREVENT Cancer Preclinical Drug Development Program. Additionally, IITRI has a $9.8 million single-award contract with NCI for preclinical toxicology of small molecule drugs and a $174.5 million single-award contract with NINDS for the Pharmacology and Toxicology for Therapeutics Program. These IDIQ vehicles enable federal agencies to efficiently access IITRI's comprehensive preclinical research capabilities on an as-needed basis, supporting critical drug development efforts across multiple therapeutic areas. Task orders under these IDVs have been awarded by various NIH institutes to conduct specific preclinical studies, ranging from toxicology assessments of cancer therapies to safety evaluations of neurological treatments.
DGBUFQYMKWB5 541715
Not listed 10 W 35th St #4, Chicago, IL 60616, USA
4/15/02 10/8/25 Eurofins Panlabs, Inc.
Eurofins Panlabs, Inc. is a foreign-owned, for-profit contract research organization registered in SAM.gov that provides comprehensive scientific and technical services to federal agencies. The company specializes in advanced research and development services, focusing on analytical chemistry, microbiology, toxicology testing, and non-clinical research to support various government research initiatives. Through its federal contract awards, Eurofins Panlabs offers a wide range of scientific testing and screening services, including receptor binding studies, safety pharmacology, predictive toxicology, and in vitro screening across multiple biological targets.
The company has received numerous federal contract awards from agencies such as the Environmental Protection Agency (EPA), National Institutes of Health (NIH), Food and Drug Administration (FDA), and Department of Veterans Affairs (VA). These contracts primarily involve providing specialized scientific services, including chemical mechanism identification, risk assessment, drug discovery support, and safety evaluations. Eurofins Panlabs has been awarded contracts for services like lead optimization screening, rodent pharmacokinetics, receptor profiling, dose response analyses, and targeted biological screening. Most of these contracts are firm-fixed-price purchase orders or delivery orders, with no specific small business set-aside designations. The contracts cover a diverse range of research areas, including drug development, chemical safety, infectious disease research, and non-clinical laboratory support.
Eurofins Panlabs holds three significant federal contract indefinite delivery vehicles (IDVs): a $20 million FDA contract for research and development services through September 2028, a $5 million NIH National Institute on Drug Abuse contract for receptor binding and predictive toxicology services through September 2028, and a $9.7 million EPA contract through December 2026 for in vitro and target-based assays. These IDVs enable the company to provide comprehensive scientific services across multiple federal agencies. The EPA contract, for instance, supports phenotypic and genomic screening to identify chemical bioactivity and mechanisms of action, while the NIH contract focuses on receptor profiling and predictive toxicology for drug abuse research. Task orders under these IDVs have ranged from $13,000 to over $600,000, demonstrating the company's versatility in supporting various federal research initiatives.
HF4LCAU68M93 541715
Not listed 6 Research Park Dr, St Charles, MO 63304, USA
2/21/14 3/14/25